Skip to main content
main-content
Top

Tip

Swipe om te navigeren naar een ander artikel

15-09-2017 | Uitgave 1/2018 Open Access

Quality of Life Research 1/2018

Health-related quality of life and its determinants in patients with metastatic renal cell carcinoma

Tijdschrift:
Quality of Life Research > Uitgave 1/2018
Auteurs:
S. de Groot, W. K. Redekop, M. M. Versteegh, S. Sleijfer, E. Oosterwijk, L. A. L. M. Kiemeney, C. A. Uyl-de Groot
Belangrijke opmerkingen

Electronic supplementary material

The online version of this article (doi:10.​1007/​s11136-017-1704-4) contains supplementary material, which is available to authorized users.

Abstract

Purpose

Based on improvements of progression-free survival (PFS), new agents for metastatic renal cell carcinoma (mRCC) have been approved. It is assumed that one of the benefits is a delay in health-related quality of life (HRQoL) deterioration as a result of a delay in progression of disease. However, little data are available supporting this relationship. This study aims to provide insight into the most important determinants of HRQoL (including progression of disease) of patients with mRCC.

Methods

A patient registry (PERCEPTION) was created to evaluate treatment of patients with (m)RCC in the Netherlands. HRQoL was measured, using the EORTC QLQ-C30 and EQ-5D-5L, every 3 months in the first year of participation in the study, and every 6 months in the second year. Participation started as soon as possible following a diagnosis of (m)RCC. Random effects models were used to study associations between HRQoL and patient and disease characteristics, symptoms and treatment.

Results

Eighty-seven patients with mRCC completed 304 questionnaires. The average EORTC QLQ-C30 global health status was 69 (SD, 19) before progression and 61 (SD, 22) after progression of disease. Similarly, the average EQ-5D utility was 0.75 (SD, 0.19) before progression and 0.66 (SD, 0.30) after progression of disease. The presence of fatigue, pain, dyspnoea, and the application of radiotherapy were associated with significantly lower EQ-5D utilities.

Conclusions

Key drivers for reduced HRQoL in mRCC are disease symptoms. Since symptoms increase with progression of disease, targeted therapies that increase PFS are expected to postpone reductions in HRQoL in mRCC.

Onze productaanbevelingen

BSL Podotherapeut Totaal

Binnen de bundel kunt u gebruik maken van boeken, tijdschriften, e-learnings, web-tv's en uitlegvideo's. BSL Podotherapeut Totaal is overal toegankelijk; via uw PC, tablet of smartphone.

Extra materiaal
Literatuur
Over dit artikel

Andere artikelen Uitgave 1/2018

Quality of Life Research 1/2018 Naar de uitgave

Special Section: Measuring What Matters (by invitation only)

Prioritizing research topics: a comparison of crowdsourcing and patient registry